Jia Liu

Jia Liu

Auto-generated profile, based on publicly available information

Jia Liu

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YLYali Liu
Yali Liu
WCWenjie Chen
Wenjie Chen
YTYingxin Tan
Yingxin Tan
XYXingyue Yang
Xingyue Yang
JLJia Liu
Jia Liu
BLBaoyan Liu
Baoyan Liu
Purpose. To analyze and compare the clinical registration information about acupuncture and moxibustion for intervention characteristics. Methods. Clinical trials from the International Clinical Trials Registry Platform of the World Health Organization in acupuncture and moxibustion were comprehensively collected from 2013 to 2015; data were independently screened and extracted by two retrievers, and relevant data involving either basic descriptions or intervention characteristics were analyzed. Results. 425 acupuncture and moxibustion registered clinical trials were included; 88.00% (374/425) were designed as controlled studies, among which 38.59% (164/425) had sham acupuncture as the control group. The most common diseases were pain‐related at approximately 19.29% (82/425) of trials. Reports on the intervention information in these acupuncture and moxibustion clinical studies were not sufficiently presented; these reports included the reporting of names of points (39.8%), the method of needle stimulation (32.5%), needle type (29.6%), needle retention time (34.1%), the number of treatment sessions (22.4%), and the frequency and duration of treatment sessions (38.1%). Conclusion. The registration information for the clinical trials of acupuncture and moxibustion was quite low according to this investigational study. Steps should be taken to improve the quality of acupuncture and moxibustion registration information.

17 September 2025 in Integrative Medicine Research
Verified
Journal Article
Open access
YSYouzhu Su
Youzhu Su
JLJia Liu
Jia Liu
YWYuxian Wang
Yuxian Wang
XXXiao Xiao
Xiao Xiao
RLRui Liu
Rui Liu
JLJianping Liu
Jianping Liu
Menopausal syndrome is a common condition in women during menopause, characterized by hormonal imbalances and various symptoms that negatively impact quality of life. Ding Kun Dan (DKD), a traditional Chinese herbal medicine, has been used to alleviate these symptoms, but its clinical efficacy and safety require further evaluation. A systematic search of eight databases was conducted through March 15, 2025. Randomized controlled trials (RCTs) were included if DKD was used alone or with conventional Western treatments. The primary outcome was the Kupperman Index; secondary outcomes included the Pittsburgh Sleep Quality Index, SF-36, Self-Rating Anxiety Scale, Self-Rating Depression Scale, estradiol, follicle-stimulating hormone, luteinizing hormone, and adverse events. Meta-analysis was performed using RevMan 5.4.1 and Stata 17. A total of 21 RCTs involving 1981 participants were included. DKD combined with menopause hormone therapy (MHT) demonstrated superior efficacy in improving overall symptoms, sleep quality, quality of life, and reducing anxiety and depression, with a positive impact on hormone levels and fewer adverse events. DKD alone also showed comparable effects to MHT in improving symptoms and hormone levels. Additionally, DKD combined with oryzanol positively impacted hormone levels. DKD, both alone and in combination with MHT or oryzanol, demonstrates potential therapeutic effects for managing menopausal symptoms, but due to the low quality of included studies, results should be interpreted cautiously. Larger, high-quality RCTs are needed to confirm these findings. PROSPERO, CRD42024621022.

19 May 2026 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
XCXue Cao
Xue Cao
XWXin Wang
Xin Wang
YTYukun Tian
Yukun Tian
XMXiangran Meng
Xiangran Meng
YQYuning Qin
Yuning Qin
JLJia Liu
Jia Liu
Background: Stroke is the second leading cause of death and the third leading cause of disability-adjusted life years lost. A narrow therapeutic window and the complex, dynamic nature of stroke pathophysiology limit current neuroprotective therapies. Angong Niuhuang Pill (ANP) is a traditional Chinese medicine emergency prescription used to treat acute conditions and is reported to have neuroprotective effects. The aim of this review was to evaluate the neuroprotection of ANP and to assess its efficacy and safety in the treatment of stroke. Methods: This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched four databases and selected studies that met the inclusion criteria (n = 16). The methodological quality was assessed using SYRCLE risk of bias tool (for animal studies), the Cochrane Risk of Bias tool (for Randomised Controlled Trials (RCTs)), and AMSTAR 2 (for systematic reviews/meta-analyses). Data were integrated using a narrative synthesis method. Results: 12 preclinical studies suggested that ANP may provide neuroprotection in stroke via multiple pathways, half of them indicating anti-cell death properties. Two high-quality preclinical studies examine the mechanism of ANP in ischemic stroke (IS), namely via the PI3K/AKT axis and microcirculation. One RCT showed that ANP increased the proportion of patients achieving an mRS score of 0-2 at six months in patients with basal ganglia haemorrhage (26.2% vs. 2.6%) and the other one, which exhibits high methodological quality, showed for patients with moderate-to-severe acute IS, ANP showed no overall benefit in day-14 infarct or oedema volumes, although a significant reduction was observed in the large artery atherosclerosis subgroup (-12.3 mL, P = 0.03). Two meta-analyses indicated that ANP was associated with higher GCS (MD = 2.01, 95% CI [1.04, 2.98], P < 0.00001) and lower NIHSS scores, but both had low methodological quality. There was no statistically significant difference in the incidence of adverse events between the two groups. Discussion: This review found that ANP has a relatively definite neuroprotective effect and can improve the clinical efficacy of stroke patients. However, due to the limited number of included studies and significant differences in study design, study population, and outcome definition, the existing evidence shows considerable heterogeneity, resulting in relatively low study quality and making reliable quantitative meta-analysis difficult. Future research should use relevant quality assessment tools in study design and implementation to enhance the credibility of evidence and thereby promote the generation of high-quality evidence. Conclusion: This review synthesizes evidence of neuroprotective effect and clinical effectiveness, suggesting potential neuroprotective benefit with an overall favorable safety profile.

14 May 2025 in Asian Journal of Surgery
Verified
Journal Article
Open access
MWMeng-Qi Wang
Meng-Qi Wang
HLHeng-Chang Liu
Heng-Chang Liu
WHWenyun Hou
Wenyun Hou
JLJia Liu
Jia Liu